Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome

Thrombosis and Haemostasis

Volumn 107, Issue 3, 2012, Pages 423-429

  Breen, Karen A ^a   Seed, Paul ^b   Parmar, Kiran ^a,b   Moore, Gary W ^a   Stuart Smith, Sara E ^a   Hunt, Beverley J ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Complement activation

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C3A; COMPLEMENT FRAGMENT BB; INTERLEUKIN 6; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LABOR COMPLICATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOSIS;

ADULT; AGED; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT ACTIVATION; COMPLEMENT C3A; COMPLEMENT FACTOR B; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PREGNANCY; YOUNG ADULT;

EID: 84857751661     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-08-0554     Document Type: Article

References (23)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Shi W, Krilis SA, Chong BH, et al. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 1990; 20: 231-236.
3. de Groot PG, Lutters B, Derksen RH, et al. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 2005; 3: 1993-1997.
4. Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol 2006; 176: 1305-1310.
5. Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211-220.
6. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD, Holers VM, Salmon JE. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112: 1644-1654.
7. Pierangeli SS, Girardi G, Vega-Ostertag M, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52: 2120-2124.
8. Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106: 2340-2346.
9. Shamonki JM, Salmon JE, Hylek E, et al. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007; 196: 167 e1-5.
10. Salmon JE, Heuser C, Triebwasser M, et al. Mutations in Complement Regulatory Proteins Predispose to Preeclampsia: A Genetic Analysis of the PROMISSE Cohort. PLoS Med. 8: e1001013.
11. Oku K, Atsumi T, Bohgaki M, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009; 68: 1030-1035.
12. Devreese KM, Hoylaerts MF. Is there an association between complement activation and antiphospholipid antibody-related thrombosis? Thromb Haemost 104: 1279-1281.
13. Mold C, Tamerius JD, Phillips G, Jr. Complement activation during painful crisis in sickle cell anemia. Clin Immunol Immunopathol 1995; 76: 314-320.
14. Lynch AM, Murphy JR, Byers T, et al. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol 2008; 198: 385 e1-9.
15. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737-1740.
16. Mehta CR, Patel NR. Exact logistic regression: theory and examples. Stat Med 1995; 14: 2143-2160.
17. Urbanus RT, Siegerink B, Roest M, et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009; 8: 998-1005.
18. Opatrny L, David M, Kahn SR, et al. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006; 33: 2214-2221.
19. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3: 1231-1238.
20. Pengo V, Biasiolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93: 1147-1152.
21. Meroni PL, Borghi MO, Raschi E, et al. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7: 330-339.
22. Kelly RJ, Hill A, Arnold LM, et al. Long term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011; prepub online.
23. Al-Akash SI, Almond PS, Savell VH, Jr., et al. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 26: 613-619.